GRI Bio, Inc. (NASDAQ:GRI – Free Report) – Investment analysts at HC Wainwright dropped their Q2 2026 earnings estimates for shares of GRI Bio in a report released on Thursday, May 14th. HC Wainwright analyst M. Keller now expects that the company will earn ($1.15) per share for the quarter, down from their prior forecast of ($0.21). The consensus estimate for GRI Bio’s current full-year earnings is ($3.49) per share. HC Wainwright also issued estimates for GRI Bio’s Q3 2026 earnings at ($0.95) EPS, Q4 2026 earnings at ($0.96) EPS, FY2026 earnings at ($4.41) EPS, FY2027 earnings at ($0.26) EPS and FY2028 earnings at ($0.20) EPS.
GRI has been the topic of a number of other research reports. Weiss Ratings restated a “sell (e+)” rating on shares of GRI Bio in a report on Tuesday, April 21st. Wall Street Zen downgraded shares of GRI Bio to a “strong sell” rating in a report on Saturday, January 31st. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, GRI Bio presently has an average rating of “Hold” and an average price target of $1,008.00.
GRI Bio Trading Up 5.4%
GRI Bio stock opened at $2.14 on Tuesday. The company has a market capitalization of $3.79 million, a P/E ratio of -0.01 and a beta of -1.22. The firm’s fifty day simple moving average is $2.41 and its 200-day simple moving average is $14.29. GRI Bio has a 1-year low of $1.97 and a 1-year high of $80.36.
GRI Bio (NASDAQ:GRI – Get Free Report) last released its earnings results on Wednesday, May 13th. The company reported ($1.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.01).
About GRI Bio
GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.
Featured Stories
- Five stocks we like better than GRI Bio
- Why Trump’s Amazon Stock Sale May Not Matter at All
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
- Is Everspin Technologies the Next AI Edge Breakout?
Receive News & Ratings for GRI Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRI Bio and related companies with MarketBeat.com's FREE daily email newsletter.
